NCT00718757View on ClinicalTrials.gov

Irinotecan, Vincristine, and Dexamethasone In Children With Relapsed And/Or Refractory Hematologic Malignancies

PHASE1CompletedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

January 31, 2005

Primary Completion Date

January 31, 2009

Study Completion Date

January 31, 2009

Conditions
Non-Hodgkins LymphomaHodgkin's DiseaseAcute Lymphoblastic Leukemia
Interventions
DRUG

Dexamethasone

5 doses given on Days 6-10

DRUG

Irinotecan

20 mg/m2/day IV, 10 doses given on Days 1-5, 8-12

DRUG

Vincristine

"1.5 mg/m2/day IV (max 2 mg), 2 doses given on Days 1,8~\* Patients \< 1 year of age or \< 10kg in weight: Vincristine 0.05 mg/kg"

Trial Locations (2)

38105

St. Jude Children's Research Hospital, Memphis

92123

Rady's Children Hospital San Diego, San Diego

All Listed Sponsors
lead

St. Jude Children's Research Hospital

OTHER

NCT00718757 - Irinotecan, Vincristine, and Dexamethasone In Children With Relapsed And/Or Refractory Hematologic Malignancies | Biotech Hunter | Biotech Hunter